Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: Expert Opin Drug Discov. 2011 Feb;6(2):109–127. doi: 10.1517/17460441.2011.547189

Figure 4.

Figure 4

Density of striatal nerve terminal Glu immuno-gold labeling (# gold particles/um2) within VGLUT-1 labeled and unlabeled nerve terminals following administration of 6-OHDA. 6-months following the nearly complete loss of striatal DA, the increase in the density of Glu immuno-gold labeling was identical in both VGLUT-1 labeled and unlabeled striatal nerve terminals compared to the control (CTL) group. Values are means ± S.E.M.

* - p < .05 compared to the respective control group using an ANOVA.